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Abstract
Background: Several studies have shown that cocoa and cocoa-containing foods have the potential to lower blood
pressure and improve endothelial function. Most of the studies reporting the beneficial effects of dark chocolate on
blood pressure have been short (≤ 4 weeks). The aim of the present 8-wks (weeks) study was to assess the effects of
regular consumption of dark chocolate during a reduced snack consumption intervention on blood pressure and other
cardiovascular risk factors in mildly hypertensive individuals.
Design: This was a randomized, controlled, cross-over trial involving 22 adults (8 women, 14 men), aged 33–64 y,
BMI 27.7 ± 3.7 kg/m2 with mild hypertension. During the intervention period (8-wks) the participants reduced
the intake of habitual snacks and replaced them with dark chocolate (49 g/day). In the control period, they only
reduced the snacks without any added chocolate. Data (blood lipid profile, glucose, insulin, 24 h blood pressure)
was collected in the beginning and end of both periods (intervention and control), and some variables also in
the run-in and run-out periods (weight, body fat percentage, blood pressure, arterial stiffness index, diet and
physical activity).
Results: Daily consumption of dark chocolate had no effects on 24 h blood pressure, resting blood pressure
(mean ± SD, pre 142 ± 11.5/89 ± 8.4 mmHg vs. post 142 ± 14.2/88 ± 9.4 mmHg in systolic and diastolic blood
pressure, respectively) or arterial stiffness (mean ± SD, pre 7.68 ± 0.88 vs. post 7.76 ± 0.89).
Weight was reduced by 1.0 ± 2.2 kg during the control (reduced snack only) period, but was unchanged while
eating chocolate (p < 0.027 between the treatments).
Conclusion: The data collected in this study indicates that inclusion of dark chocolate daily in the diet had no
significant effects on blood pressure or other cardiovascular risk factors during a reduced snack period.
Trial registration: ClinicalTrials.gov identifier NCT02130141
Background
Polyphenols are plant-derived compounds; secondary
metabolites with an essential role in protection of plants
against different environmental and microbial threats
[1]. Polyphenols can be divided into flavonoids and non-
flavonoids. Flavonoids consist of six subgroups, namely
flavonols, flavan-3-ols (monomeric and polymeric struc-
tures), flavones, isoflavones, flavanones, and anthocyani-
dins. Phenolic acids, stilbenes, lignans and other
polyphenols belong to non-flavonoid group.
Unlike vitamins, polyphenols are not essential nutri-
ents. However, regular intake of polyphenols may have
favorable effects on health and risk of chronic diseases.
Also, several clinical trials have shown a favorable effect
of flavonoids on cardiovascular disease (CVD) risk fac-
tors [2, 3]. The health effects of polyphenols depend on
their bioavailability [4], e.g., the rate and extent of their
absorption and metabolism, and the chemical structure
of the molecule.
Cocoa and cocoa-containing foods, such as dark choc-
olate, represent a very rich source of flavonoids as they
provide a higher content of flavonoids per serving than
red wine or tea [5]. Cocoa contains monomeric flavanols,
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namely epicatechin and catechin, and oligomeric procya-
nidins [6]. The consumption of cocoa products has been
shown to have an influence on CVD risk factors [2, 7],
and cocoa intake has been inversely associated with car-
diovascular mortality [8]. Epidemiological studies have
also reported an inverse association between chocolate
consumption and risk of CVD [9] and heart failure [10].
In human intervention studies dark chocolate consump-
tion has shown health promoting effects on blood pres-
sure [11, 12], total-, LDL- and HDL-cholesterol [11, 13],
and also on insulin resistance and sensitivity [11].
The beneficial health effects of cocoa have been espe-
cially related to endothelial function [14]. Consumption of
cocoa and chocolate has been shown to decrease blood
pressure and to ameliorate flow mediated dilation (FMD)
[7]. Moreover, isoflavones, anthocyanins and cocoa flavan-
3-ols in particular, have been associated with or have been
shown to have a positive effect on arterial stiffness [15].
Most of the studies reporting the beneficial effects of
dark chocolate on blood pressure have been short (i.e., 2
to 4 wks) and the daily dose substantial, as much as
100 g/day [16–18]. Therefore, in this study we wanted to
find out if a more reasonable portion (49 g/day dose) for
a longer period of time would have an effect on blood
pressure and arterial stiffness. The aim of the present
cross-over study was to examine the effects of daily con-
sumption of dark chocolate during a reduced snack con-
sumption period for 8 wks on blood pressure (primary
outcome) and other cardiovascular risk factors in adults
with mild hypertension. For ethical reasons, we wanted
to avoid deliberate positive energy balance in our partici-
pants with an increased risk for chronic diseases. There-
fore, during both the intervention (dark chocolate) and
control (no chocolate) periods, the energy intake in the
habitual diet was reduced by ways of reducing the par-
ticipant’s daily snack consumption.
Methods
Participants
Thirty healthy volunteers (19 men, 11 women) were re-
cruited by flyers and newspaper advertisements. To be
included into the study, the participants had to have
mild hypertension (140–159 mmHg systolic blood pres-
sure (SBP) or 90–99 mmHg diastolic blood pressure
(DBP) according to the Finnish Hypertension Society)
and BMI < 35 kg/m2. Exclusion criteria were smoking
and regular use of medications for cardiovascular
disease, diabetes or asthma. Twenty two participants
(14 men and 8 women), 33–64 years old, mean age 45.8
(SD 8.3) years with a BMI of 27.9 (SD 3.6) kg/m2 com-
pleted the study and were included in the final analysis.
Eight participants withdrew during the study for per-
sonal reasons or because their blood pressure exceeded
the accepted level (159/99 mmHg). Written informed
consent was obtained from all participants. The study
protocol was reviewed by the Ethics Committee of the
Helsinki and Uusimaa Hospital District, Finland. The
study was registered at the US National Institutes of
Health clinical trials database (ClinicalTrials.gov), identi-
fier NCT02130141.
Study design
The study was a randomized, controlled, 8-wks cross-
over intervention with two arms (Fig. 1). The partici-
pants were randomly assigned to one of the two arms
(denoting order of interventions) after stratification by
sex and BMI. The run-in phase before, and the run-out
phase after the intervention and control periods, as well
as the wash-out period between them, were all four wks
in duration. The participants were asked to maintain
their normal dietary and lifestyle habits throughout the
study except for the snack restriction. During both the
intervention and the control periods, the participants
were instructed to reduce their habitual daily snacking,
with an aim to reduce energy intake by 250 kcal/day.
During the dark chocolate period (8 wks) the partici-
pants replaced their habitual snacks with dark chocolate
(49 g/day, equals 262 kcal). During the control period,
reduced snack consumption was not replaced by dark
chocolate. The reduction of energy intake due to re-
duced snack consumption was planned individually, to-
gether with a nutritionist, and based on self-reported
food intake and individual preferences. The compliance
with the snack restriction was evaluated at personal
meetings at the halfway of both intervention periods.
The intervention chocolate was Karl Fazer’s dark choc-
olate (70 % cacao). The participants were asked to eat
seven pieces of the chocolate (7 g) daily, for a daily in-
take of 49 g/day. The analyzed content of proanthocya-
nidins (referred as flavanols, by degree of polymerization
1–10) of dark chocolate was 1230 mg/100 g (fresh
weight) [19]. The dark chocolate contained total fat
41 g, protein 9 g, carbohydrate 35 g, fibre 11 g and so-
dium 46 mg per 100 g fresh weight. All the dark choc-
olate was provided at the first visit of the chocolate
treatment period. The daily timing for the chocolate
snack was free. White chocolate was allowed throughout
the study, but milk chocolate was not.
Methods
Blood samples were taken and 24 h blood pressure was
measured in the beginning and end of both intervention
periods. Additionally, blood pressure, weight and an-
thropometrics, as well as diet and physical activity, were
assessed also in the beginning of the run-in period and
in the end of run-out period. These visits were also for
compliance checks, meetings with the study nurse, and
dietary counselling.
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Blood pressure and cardio-ankle vascular index (CAVI)
Ambulatory 24 h blood pressure (systolic and diastolic
blood pressure of 24 h average, day time and night time
separately) was monitored on a day of standard physical
activity, with an adequate cuff for the size of the pa-
tient’s arm. Welch Allyn ABPM 6100 (Welch Allyn Inc,
USA) validated according to the protocol of the Finnish
Hypertension Society, was used. The recorder was pro-
gramed to take blood pressure measurements every
20 min during daytime and every 45 min during night-
time. The data were considered valid when ≥ 80 % of all
measurements were acceptable. Participants kept a brief
diary to record timing of activities, sleep and posture
when measuring blood pressure.
Cardio-Ankle Vascular Index (CAVI) was measured
by VaSera (Fukuda Denshi Co., Ltd., Tokyo, Japan).
CAVI is an index reflecting the stiffness of the artery
from the heart to ankles. The calculation of CAVI is
based on the stiffness parameter β which is measured by
carotid echography and is not affected by blood pres-
sure [20]. The echography acquires an oscillometric
method for blood pressure measurement, and hence it
indicates the natural vascular stiffness. In addition, it
measures blood pressure from all four limbs, at first
from the right brachial and ankle and then from the left
brachial and ankle. Thus, arteries at the right and left
sides are alternately pressurized while the other side re-
mains open.
Weight and body composition
Weight and body composition were measured by body
composition analysis device InBody720 (InBody 720,
Body Composition Analyzer, Biospace Co. Ltd) with par-
ticipants in underwear, in a fasted state, and within
20 min after bladder emptying.
Blood samples and oral glucose tolerance test
Blood samples were drawn after a 10–12 h overnight fast
in the beginning and after the 8 wk intervention periods.
Blood samples were collected for determination of lipids
(total cholesterol, LDL cholesterol, HDL cholesterol, tri-
glycerides), glucose and insulin. Serum (without anti-
coagulant) and plasma (EDTA-coated tubes) were
separated by centrifugation (10 min at 3000 rpm) and
frozen at −20 °C until analysis. In addition, an oral glu-
cose tolerance test (OGTT) with 75 g of glucose in
300 ml water was administered to all participants before
and after the intervention periods.
Total cholesterol, triglyceride, HDL- and LDL choles-
terol concentration were measured enzymatically. Glu-
cose was measured by the hexokinase method and
insulin was assayed by the chemiluminescent immuno-
assay method. To assess glucose response and total insu-
lin secretion, areas under the response curve to glucose
and insulin (GluAUC, InsAUC) were calculated from 0
(fasting), 15, 30, 45, 60, 90 and 120 min serum glucose
and insulin concentrations using the trapezoid rule [21].
Fig. 1 Study design and data collection. After a cocoa free run-in phase of 4 weeks, participants were randomly assigned to follow the snack
restriction or receive 49 g dark chocolate in addition to snack restriction. Successively, participants entered a further cocoa-free washout phase
of 4 weeks and then were crossed over to the other treatment. The final phase was the run-out period of 4 weeks. Abbreviations: BP = clinical
blood pressure; CAVI = cardio-ankle vascular index; WT = weight and other; DR = diet records; anthropometrics; AMPM = 24-h ambulatory blood
pressure; BS = blood samples; OGTT = oral glucose tolerance test; PAR = physical activity records
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Homeostasis model assessment of insulin resistance
(HOMA) was used as a simple index for insulin sensitiv-
ity. HOMA was calculated by the formula: HOMA=
fasting serum insulin (mU/l) × fasting serum glucose
(mmol/L)/22.5 [22].
Dietary analyses and other confounders
Dietary intake was repeatedly evaluated to ensure the
success of the snack restriction and to give an indica-
tion of other dietary components related to the out-
come variables. The participants completed a 3-day
food diary (2 working days and 1 weekend day) five
times during the study (the intervention periods, the
run-in, wash out and run-out periods). The consump-
tion of all foods and drinks was recorded during these
days. Household measures and standard units were
used to describe amounts of foods consumed. The vol-
unteers received detailed instructions on how to fill in
the diaries, and a nutritionist performed an interview
to review and clarify the food records. Food and nutri-
ent intakes were calculated by using AivoDiet software
(version 2.0.2.3.; Aivo Finland Oy, Turku, Finland), which
is based on Fineli, the Finnish food composition database
(The National Institute for Health and Welfare, Helsinki,
Finland, 2014). According to self-report, all participants
consumed the requested daily amount of dark chocolate.
Additionally, the participants refrained from consuming
cocoa or chocolate from sources other than the study
products during the dark chocolate intervention and con-
trol periods. Moreover, the participants did not consume
any milk or dark chocolate during the run-in, run-out, or
wash-out periods.
Participants were asked to maintain their usual level of
physical activity during the study. Additionally, partici-
pants’ physical activity and health status, use of medica-
tion, as well any adverse events, were evaluated by a
questionnaire concerning the previous week before the
data collection.
Statistics and power calculation
Statistical analyses were performed by using IBM SPSS
Statistics for Windows (version 21.0; IBM, New York,
NY). The normality of the analyzed variables was tested
using Shapiro-Wilk’s W-test. If the distribution was not
normal, logarithmic transformations were done before
the analyses. The differences for the variables between
two arms at the baseline were tested with Student’s t test
for independent samples. Differences in the variables
measured between the chocolate and control periods
were analyzed with repeated measures ANCOVA, and
baseline value as covariate were used. The power cal-
culation was based on data from the meta-analysis by
Reid et al. [23]. The required number of participants
was 23, when using a cross-over design, with an
expected mean difference of 2.8 (expected SD 4.6) mmHg
in systolic blood pressure (α- risk = 0.05, power =0.80).
Results
There were no significant differences in measured vari-
ables between the two arms at baseline. Neither 24 h
nor clinical blood pressure was significantly affected by
the dark chocolate intervention. However, blood pres-
sure decreased significantly over the entire study. Twelve
of the 22 participants’ status improved from hypertensive
to normotensive. From baseline to the end of the study,
mean (SD) systolic and diastolic blood pressures among
all participants were reduced by 7 mmHg (12.2) and
3 mmHg (7.9), respectively (p = 0.016, data not shown).
The intervention trial had no effect on CAVI.
Weight decreased 1.0 kg (± SD 2.2) after the control
period where no dark chocolate was consumed (Table 1).
In contrast, there was no decrease in weight during the
dark chocolate intervention. The mean difference in
weight change between the periods was 1.0 kg (p = 0.027).
The percentage of body fat and fat mass tended to de-
crease during both chocolate intervention and control pe-
riods, but the changes were not significant. Other
anthropometric measures remained unchanged. More-
over, there were no significant changes or differences in
lipid profile, blood glucose or blood insulin during the trial
or between the intervention and control periods (Table 2).
According to the 3-d food records, calcium intake was
higher during the control period than during the dark
chocolate period (Table 3). There were no other signifi-
cant differences in nutrient intake between the two pe-
riods. Physical activity neither changed during the study
nor differed between the intervention and control period
of the study. The average time spent on leisure time,
moderate or vigorous exercise, was on average 28 min
per day (data not shown).
Discussion
In this study, participants limited their habitual snack
consumption twice for an 8-wk period. During one of
these periods, the snacks were replaced with dark choc-
olate. As a consequence of snack restriction, the partici-
pants achieved a small weight loss, which was restrained
by the dark chocolate consumption. Apart from that, the
study found neither harmful, nor positive, health effects
of chocolate on CVD risk factors in mildy hypertensive
participants.
Meta-analyses have concluded that cocoa-rich prod-
ucts may reduce blood pressure [23]. However, there is
no clear separation between chocolate, and cocoa or
flavan-3-ols as such, and conclusions are inferred from
the above-mentioned compounds together. Another
challenge in randomized, controlled trials, is which com-
pound or product should be used as the control. If the
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aim is to have two treatments with equal energy intake,
a control product is required.
In the present study, we investigated the effect of dark
chocolate on blood pressure without using control prod-
ucts. In previous studies, where dark chocolate was con-
sumed without a control product [12, 13, 24–26], or
with a lycopene capsule [27] as the “control” treatment,
only Almoosawi et al. [24] and Desch et al. [12] found a
significant effect on blood pressure. In these studies, par-
ticipants received 20 g polyphenol-rich dark chocolate
with 500 and 1000 mg polyphenols for 2 weeks, and
either 6 or 25 g/day of flavanol-rich dark chocolate for
3 months, respectively. Researchers proposed that the
observed effects of polyphenol –rich dark chocolate
were linked to improved cortisol metabolism in their
overweight and obese participants [24]. In the latter
study, all except one patient received at least one antihy-
pertensive agent, hence the possible influence of medica-
tions couldn’t be excluded. Also, as the authors
mentioned, they could not ignore that, apart from a true
antihypertensive effect of dark chocolate, regression to
the mean might also have been responsible for the ob-
served BP reductions [12].
All other studies [11, 16–18, 28–31], which reported
the ability of dark chocolate to lower blood pressure,
used white chocolate, cocoa butter or chocolate bars
Table 1 Blood pressure and anthropometrics before and after the 8-wk intervention periods
Dark chocolate period Control period
baselinea 8 wk baseline 8 wk pb
clinical SBPc (mmHg) 142 (11.5) 142 (14.2) 142 (11.7) 141 (9.9) ns.
clinical DBPd (mmHg) 89 (8.4) 88 (9.4) 89 (9.0) 88 (10.1) ns.
24 h SBP (24 h)e (mmHg) 137 (11.4) 138 (9.9) 140 (9.8) 142 (10.5) ns.
24 h DBP (24 h) (mmHg) 82 (10.2) 82 (9.2) 84 (9.4) 84 (9.6) ns.
day SBP (24 h) (mmHg) 142 (11.2) 143 (9.2) 144 (7.8) 146 (10.6) ns.
day DBP(24 h) (mmHg) 86 (10.2) 86 (8.8) 87 (9.0) 88 (10.1) ns.
night SBP(24 h) (mmHg) 120 (11.4) 120 (13.3) 121 (10.1) 125 (11.8) ns.
night DBP(24 h) (mmHg) 69 (10.1) 67 (10.4) 68 (10.6) 70 (8.4) ns.
night SBP dipf (%) 15.1 (3.7) 16.4 (5.7) 15.8 (3.9) 14.3 (5.8) ns.
night DBP dip (%) 20.4 (5.1) 21.6 (6.2) 21.9 (6.9) 20.5 (6.5) ns.
CAVIg (right) 7.68 (0.88) 7.76 (0.89) 7.92 (0.98) 7.87 (0.90) ns.
CAVI (left) 7.63 (0.88) 7.60 (0.88) 7.74 (0.94) 7.77 (0.90) ns.
weight (kg) 85.5 (16.4) 85.4 (16.0) 85.7 (16.5) 84.7 (16.4) 0.027
fat mass (kg) 24.4 (10.3) 23.7 (10.2) 24.3 (9.9) 23.5 (9.8) ns.
body fat (%) 28.0 (9.0) 27.2 (9.2) 27.8 (8.6) 27.3 (9.1) ns.
visceral fat (mm2) 125 (34) 123 (35) 126 (34) 121 (33) ns.
aData are given as mean ± SD; btest the change difference between two periods; csystolic blood pressure; ddiastolic blood pressure; e24 h ambulatory blood
pressure; fproportional dip from day time (awake) average BP to night time (sleeping) average BP; gcardio-ankle vascular index
Table 2 Serum glucose, insulin and lipids before and after the 8-wk intervention periods
Dark chocolate period Control period
baselinea 8 wk baseline 8 wk pb
glucose (mmol/L) 5.3 (0.4) 5.4 (0.3) 5.2 (0.4) 5.4 (0.4) ns.
insulin (mU/L) 8.9 (4.6) 8.6 (3.0) 9.4 (3.5) 9.4 (3.7) ns.
HOMA indexc 2.12 (1.17) 2.06 (0.71) 2.09 (1.00) 2.27 (0.96) ns.
GLUAUC
d 14.8 (2.8) 14.7 (2.4) 14.3 (2.6) 14.5 (2.5) ns.
INSAUC
d 114.4 (71.0) 112.8 (57.7) 110.8 (73.7) 110.4 (64.4) ns.
total cholesterol (mmol/L) 5.6 (1.1) 5.6 (1.1) 5.6 (1.1) 5.4 (1.1) ns.
LDL- cholesterol (mmol/L) 3.6 (1.0) 3.6 (1.0) 3.6 (0.9) 3.4 (1.0) ns.
HDL- cholesterol (mmol/L) 1.5 (0.3) 1.6 (0.3) 1.5 (0.3) 1.6 (0.3) ns.
triglyserides (mmol/L) 1.23 (0.47) 1.19 (0.50) 1.27 (0.42) 1.16 (0.48) ns.
aData are given as mean ± SD; btest the change difference between two periods; cthe homeostasis model assessment index; dareas under the response curve to
glucose and insulin were calculated from the fasting, 15, 30, 45, 60, 90 and 120 min serum glucose and insulin concentrations using the trapezoid rule
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without flavanols as a control, in order to create condi-
tions with equal energy intake. The lack of control prod-
uct is a limitation of our study. However, it is not clear
whether these control “placebos” are neutral, since it
cannot be excluded that the placebo itself might have in-
cluded something which led to physiologic effects and
detected changes.
In the study by Allen et al. [32] both dark chocolate
and dark chocolate with canola sterols decreased blood
pressure when the diet was based on the AHA diet
(The American Heart Association’s Diet). It was con-
cluded that the adoption of AHA diet could have led to
modest reductions in blood pressure during the course
of the study. In our study, the participants were re-
cruited based on their mild hypertension. Twelve of the
22 participants’ status improved from hypertensive to
normotensive in the course of the present study, but
without a clear link to dark chocolate consumption.
Similar to the findings in the study by Allen et. al. [32],
the overall changes in the diet may have contributed
the most to the positive trends seen in the current
study. While the different energy intakes in the two pe-
riods may be regarded as a limitation in our study, the
intention was to study a natural situation where indi-
viduals add chocolate to their existing diet. In order to
avoid deliberate positive energy balance, the baseline
energy intakes in both arms were first reduced by
restricting the consumption of snacks.
Flow-mediated dilation (FMD) of the peripheral con-
duit arteries is one of the most widely used tests of
endothelial function. CAVI is a new method which re-
flects the stiffness of the whole arterial segment, and it
correlates with FMD [33]. CAVI changes over a short
period of time in response to alterations in circulatory
conditions; it is sensitive to subclinical changes in major
arteries before impairment and it can be a reliable indi-
cator of treatment effectiveness or modification in life-
style [34]. Healthy lifestyle, physical exercise and
smoking cessation, for example, prevent and treat early
vascular aging [35, 36].
In contrast to results from our study, consumption of
dark chocolate has had a beneficial effect on vascular func-
tion by improving endothelial function, measured by flow
mediated dilatation both in short-terms (i.e., 2 wks) inter-
ventions [17, 37] and in acute-response studies [38, 39]
without affecting arterial stiffness [39]. The duration of
these studies was considerably shorter in comparison to
ours. The quantity of daily dark chocolate consumption in
the aforementioned studies was similar to, or substantially
more (46 or 100 g/day) than the 49 g/day dose in the
current study.
In the one-year intervention study of Curtis et al. [40]
conducted in postmenopausal Type 2 Diabetes patients,
dark chocolate consumption had a positive effect on ar-
terial stiffness in a sub-group analysis of 35 participants.
In a cross-over study where healthy participants were
assigned to receive five treatments of daily intake of
cocoa power with different doses of flavanols for one
week each [41], cocoa consumption improved FMD and
arterial stiffness. In our study, the amount of flavanols
from dark chocolate was smaller than in the above-
mentioned studies. Moreover, the power calculation was
based on blood pressure as the main outcome, not arter-
ial stiffness. The length of our intervention might also
Table 3 Mean daily intake of selected nutrients according to the 3-d food records
Chocolate period Control period
baselinea 8 wk baseline 8 wk pb
Energy (kcal) 2023 (623) 2137 (632) 2068 (505) 2214 (656) ns.
Carbohydrates (g) 217 (93) 238 (93) 226 (69) 241 (82) ns.
Protein (g) 87 (20) 87 (29) 85 (24) 97 (37) ns.
Fat (g) 77 (28) 80 (27) 81 (22) 80 (32) ns.
saturated fat (g) 29.5 (12.1) 29.3 (10.6) 32.0 (11.5) 28.6 (12.2) ns.
monounsaturated fat (g) 26.7 (10.8) 28.7 (10.1) 26.6 (7.7) 27.6 (11.6) ns.
polyunsaturated fat (g) 11.7 (4.4) 12.8 (5.2) 12.1 (3.3) 12.2 (6.5) ns.
Fiber (g) 20.2 (4.6) 22.3 (8.4) 22.4 (8.9) 20.6 (6.4) ns.
Vitamin C (mg) 132 (60) 136 (61) 94.5 (72) 134 (94) ns.
Vitamin D (μg) 8.0 (5.1) 8.2 (4.7) 8.8 (4.3) 10.5 (9.7) ns.
Calcium (mg) 1061 (457) 1061 (493) 1036 (337) 1153 (412) 0.019
Magnesium (mg) 364 (89) 400 (115) 397 (113) 398 (112) ns.
Sodium (g) 2.9 (0.89) 2.9 (0.88) 3.0 (0.72) 3.0 (0.97) ns.
Potassium (g) 4.0 (1.0) 4.1 (1.1) 3.6 (1.3) 4.1 (1.2) ns.
aData are given as mean ± SD; btest the change difference between two periods
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have been too short to achieve significant changes in ar-
terial stiffness. In the study of Curtis et al. [40], the par-
ticipants were diabetic women whereas in our study
there were more men than women, and the participants
were otherwise healthy, except mild hypertension.
Previous studies on dark chocolate and glucose metabol-
ism have shown positive or neutral effects [28, 40]. In the
present study, we found no effects of added dark chocolate
on glucose or insulin, during the reduced snack consump-
tion intervention. Even though the exact mechanisms are
not well understood, it has been demonstrated that the
acute ingestion of dark chocolate [42] or the addition of
cocoa to various foods [43] can stimulate insulin responses
during the post-prandial period. Moreover, the consump-
tion of dark chocolate has induced positive effects on insu-
lin resistance and sensitivity in short-term (i.e., 2 to
4 weeks) studies [16, 17, 28, 30] and in one study lasting
one year [40].
Dark chocolate contains saturated fatty acids which have
shown to be atherogenic. However, the overall atherogenic
effect of a product (chocolate, in this case) is modulated by
many other ingredients, not only saturated fatty acids. For
instance, chocolate also contains linoleic and oleic acids,
known to modulate cholesterol metabolism in a health-
promoting way. Despite its saturated fatty acid content,
dark chocolate has lowered both total- and LDL cholesterol
in previous studies [11, 17, 30, 32] or has lowered one or
the other [40, 44]. Consumption of dark chocolate has in-
creased HDL cholesterol concentrations both in short- and
long-term studies including healthy and Type 2 Diabetes
patients [13, 26, 45–47].
In most studies, consumption of dark chocolate has not
had any impact on triglycerides, with the exception of two
studies where acute consumption increased triglyceride
concentration [48] and an improvement occurred when
dark chocolate and almonds were consumed as part of a
low-fat diet [49]. The amount of dark chocolate cannot ex-
plain the results obtained from studies mentioned above,
since doses were very different among them, and a dose–
response cannot be found. The amount of dark choc-
olate consumed, namely 44–45 g/day, and study
duration (8 wks), were comparable to our intervention
in two studies [32, 45]. Improvement of cholesterol
concentrations occurred even after consumption of one
third [47] or half [40] of the amount of dark chocolate,
compared to the present intervention. Diet modification
and energy-restriction could have affected the observed
changes [32, 47]. In our study, however, neither snack-
restriction nor dark chocolate consumption seemed to
have an effect on lipid concentrations.
Proportion of body fat and total fat mass tended to de-
crease during the study periods, but the change was not
significant. The result of the present study is similar to
previous studies [50, 51] which showed improvements in
anthropometrics with a energy-reduced diet including a
daily dark chocolate snack without or with the cocoa
beverage, respectively. In both studies the intervention
period was 18 weeks and the participants were over-
weight/obese women. In our study, snack restriction in-
duced a small weight loss and added consumption of
dark chocolate apparently prevented the loss. Also, in
the study of Sarria et al. [52], regular consumption of a
cocoa product rich in fibre for 4 wks showed a slight de-
crease in body fat but no change in weight.
Several intervention studies have shown that con-
sumption of dark chocolate may have beneficial effects
on cardiovascular health [7, 53]. Even if it would be
tempting to recommend dark chocolate as a daily snack,
long-term intake of chocolate could in theory have a
negative effect on the diet. Intake of chocolate may in-
crease the proportion of fat in the diet, and this conse-
quently may increase energy density and decrease
nutrient density. We did not find any significant differ-
ences in nutrient intakes during the study periods. Sur-
prisingly, we did not even see a decrease in the energy
intake during the control (no chocolate) period. One
limitation of the study was self-reported diaries which
might have given inaccurate data. The number of partic-
ipants was too small to validate the actual intake during
the intervention. However, calcium intake during the
control period was significantly higher than during the
chocolate intervention. Dairy products are usually con-
sumed as a snack, and during the control period the
participants may still have consumed more of these
products. Although calcium may, in theory, have a
blood pressure-lowering effect [54], the intakes in gen-
eral were so high in our study that it is very unlikely
the small difference had any practical significance on
blood pressure.
Conclusions
In this study, the reduced snack consumption and inclu-
sion of 49 g dark chocolate daily as part of a diet of
mildy hypertensive participants had no significant effects
on cardiovascular risk factors during 8 wks. Perhaps the
positive effects were already caused by the decreased
snack intake and therefore, the addition of dark choc-
olate failed to produce beneficial effects. However, apart
from a small effect on body weight (dark chocolate
seemingly prevented a slight decrease in body weight
during the control period), no other negative effects
were observed.
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